KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Liabilities and Shareholders Equity (2017 - 2026)

Amneal Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 9 years, most recently at $3.7 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 5.05% year-over-year to $3.7 billion; the TTM value through Dec 2025 reached $14.1 billion, up 0.99%, while the annual FY2025 figure was $3.7 billion, 5.05% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $3.7 billion at Amneal Pharmaceuticals, up from $3.6 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $4.0 billion in Q2 2022 and troughed at $3.4 billion in Q1 2025.
  • A 5-year average of $3.7 billion and a median of $3.7 billion in 2023 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: fell 9.81% in 2021 and later rose 5.05% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $3.9 billion in 2021, then decreased by 3.56% to $3.8 billion in 2022, then dropped by 8.6% to $3.5 billion in 2023, then increased by 0.83% to $3.5 billion in 2024, then grew by 5.05% to $3.7 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AMRX at $3.7 billion in Q4 2025, $3.6 billion in Q3 2025, and $3.4 billion in Q2 2025.